LPL and metabolic dysfunction-associated steatotic liver disease: Lipid-lowering variants of LPL were associated with decreased risks of both T2D (OR 0.71; 95% CI: 0.65 to 0.77; p-IVW=9.81×10-3, FDR=3.85×10-12) and NAFLD (OR 0.52; 95% CI: 0.32 to 0.84; p-IVW=7.02×10-3, FDR=3.34×10-2).